Affordable Access

Rapid and sensitive detection of SARS-CoV-2 antibodies by biolayer interferometry.

Authors
  • Dzimianski, John V
  • Lorig-Roach, Nicholas
  • O'Rourke, Sara M
  • Alexander, David L
  • Kimmey, Jacqueline M
  • DuBois, Rebecca M
Publication Date
Dec 10, 2020
Source
eScholarship - University of California
Keywords
License
Unknown
External links

Abstract

Serological testing to evaluate antigen-specific antibodies in plasma is generally performed by rapid lateral flow test strips that lack quantitative results or by high complexity immunoassays that are time- and labor-intensive but provide semi-quantitative results. Here, we describe a novel application of biolayer interferometry for the rapid detection of antigen-specific antibody levels in plasma samples, and demonstrate its utility for quantification of SARS-CoV-2 antibodies. Our biolayer interferometry immunosorbent assay (BLI-ISA) utilizes single-use biosensors in an automated "dip-and-read" format, providing real-time optical measurements of antigen loading, plasma antibody binding, and antibody isotype detection. Complete semi-quantitative results are obtained in less than 20 min. BLI-ISA meets or exceeds the performance of high complexity methods such as Enzyme-Linked Immunosorbent Assay (ELISA) and Chemiluminescent Immunoassay. Importantly, our method can be immediately implemented on existing BLI platforms for urgent COVID-19 studies, such as serosurveillance and the evaluation of vaccine candidates. In a broader sense, BLI-ISA can be developed as a novel diagnostic platform to evaluate antibodies and other biomolecules in clinical specimens.

Report this publication

Statistics

Seen <100 times